Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
New TECFIDERA® (dimethyl fumarate) data show sustained efficacy and long-term safety in a broad range of multiple sclerosis patients
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
12-oxo-phytodienoic acid, a plant-derived oxylipin, attenuates lipopolysaccharide-induced inflammation in microglia.
Neuro-Immune Interactions at Barrier Surfaces.
Novantrone
Three-Month Test-Retest Reliability of Center of Pressure Motion During Standing Balance in Individuals with Multiple Sclerosis.
Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis.
Drugs@FDA
A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis.
Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment.
A silver lining of neuroinflammation: Beneficial effects on myelination.
Social Support in Relation to Fatigue Symptoms Among Patients with Multiple Sclerosis.
Assessment of structural and functıonal vısual outcomes ın relapsıng remıttıng multıple sclerosıs wıth vısual evoked potentıals and optıcal coherence tomography.
Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
Myelinating satellite oligodendrocytes are integrated in a glial syncytium constraining neuronal high-frequency activity.
The role of global and regional gray matter volume decrease in multiple sclerosis.
Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS.
Pages
« first
‹ previous
…
72
73
74
75
76
77
78
79
80
…
next ›
last »